The moment you say “no” to considering digital health is the moment you put a time stamp on your relevance.
The evidence in the market is clear: patient-generated health data (PGHD) is an essential tool for optimized care.
Pharma companies that are now incorporating digital health devices in clinical trials need to address five important lessons before moving forward.
With healthcare costs rapidly rising, stakeholders are looking for ways to better manage the health and chronic conditions of our country’s population
Wearables data are providing drug developers with meaningful trial participant insights that go beyond a count of steps taken.
There are significant business risks to hospitals and health systems that do not adopt and utilize digital health.
Data from wearable devices are enabling sports medicine physicians to reduce and prevent injuries.
The healthcare industry is making significant investments in health IT. Specifically, healthcare organizations are looking to software as a service and cloud computing to help address population health management programs. Telehealth is gaining traction as a way to engage patients and also address care outside of the provider's four walls.
As the industry experiences changes in payment models from fee-for-service to fee-for-value, with providers and payers sharing the financial risk, it's important to make the most of digital technology to improve the physical and financial health of patients and the hospitals that treat them.